Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens

Detalles Bibliográficos
Autores principales: Maiti, Abhishek, Rausch, Caitlin R., Cortes, Jorge E., Pemmaraju, Naveen, Daver, Naval G., Ravandi, Farhad, Garcia-Manero, Guillermo, Borthakur, Gautam, Naqvi, Kiran, Ohanian, Maro, Short, Nicholas J., Alvarado, Yesid, Kadia, Tapan M., Takahashi, Koichi, Yilmaz, Musa, Jain, Nitin, Kornblau, Steven, Montalban-Bravo, Guillermo, Sasaki, Koji, Andreeff, Michael, Bose, Prithviraj, Ferrajoli, Alessandra, Issa, Ghayas C., Jabbour, Elias J., Masarova, Lucia, Thompson, Philip A., Wang, Sa, Konoplev, Sergej, Pierce, Sherry A., Ning, Jing, Qiao, Wei, Welch, John S., Kantarjian, Hagop M., DiNardo, Courtney D., Konopleva, Marina Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927994/
https://www.ncbi.nlm.nih.gov/pubmed/32499238
http://dx.doi.org/10.3324/haematol.2020.252569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927994/
https://www.ncbi.nlm.nih.gov/pubmed/32499238
http://dx.doi.org/10.3324/haematol.2020.252569

Ejemplares similares